Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Bexotegrast-treated patients demonstrated improvements in forced vital capacity (FVC) and reduced cough severity compared to placebo. Bexotegrast was well tolerated at 160 mg over 12 weeks of ...

Interstitial lung disease (ILD) causes significant morbidity and mortality in patients with systemic autoimmune rheumatic diseases. Patients at high risk of ILD should be screened using ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Following use of race-neutral lung function equations, African American and Latino pediatric ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Two differing nerandomilast doses were assessed against ...

Pulmonary function was significantly associated with frailty in community-dwelling older adults over a 5-year period, as indicated from data from more than 1000 individuals. The pulmonary function ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being ...